Lupron


Also found in: Dictionary.

Lupron

 [loo´pron]
trademark for a preparation of leuprolide, an antineoplastic agent.

leuprolide acetate (leuprorelin (UK))

Eligard, Lupron, Lupron Depot, Lupron Depot-Ped, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron-3 Month SR Depot, Prostap (UK)

Pharmacologic class: Gonadotropin-releasing hormone (GnRH) analog

Therapeutic class: Antineoplastic

Pregnancy risk category X

Action

Inhibits and desensitizes GnRH receptors, thus inhibiting gonadotropin secretion when given continuously. This inhibition causes initial increase and then profound decrease in luteinizing hormone and follicle-stimulating hormone levels and, ultimately, reduces testosterone and estrogen sex hormones.

Availability

Eligard Depot: 7.5 mg, 22.5 mg, 30 mg, 45 mg

Injection: 1 mg/0.2 ml

Lupron Depot injection: 3.75 mg/ml, 7.5 mg/ml

Lupron Depot-3 month injection: 11.25 mg, 22.5 mg

Lupron Depot-4 month injection: 30 mg

Lupron Depot-Ped injection: 7.5 mg, 11.25 mg, 15 mg

Indications and dosages

Advanced prostate cancer

Adults: 1 mg subcutaneously daily (1 mg/0.2-ml formulation). For Lupron Depot formulation, 7.5 mg I.M. monthly, 22.5 mg I.M. q 3 months, or 30 mg I.M. q 4 months. For Eligard formulation, 7.5 mg subcutaneously monthly, 22.5 mg subcutaneously q 3 months, 30 mg subcutaneously q 4 months, or 45 mg subcutaneously q 6 months.

Endometriosis

Adults: 3.75 mg I.M. (depot injection) as a single injection once monthly, or 11.25 mg I.M. q 3 months. Duration is up to 6 months.

Adjunct to iron therapy in anemia caused by uterine leiomyomas

Adults: 3.75 mg I.M. monthly or 11.25 mg I.M. q 3 months as a single dose. Recommended duration is 6 months or less.

Central precocious puberty

Children: 50 mcg/kg/day subcutaneously as a single injection, increased in increments of 10 mcg/kg/day as needed

Children weighing more than 37.5 kg (82.5 lb): Initially, 15 mg of Depot-Ped I.M. q 4 weeks, increased in increments of 3.75 mg q 4 weeks as needed

Children weighing 25 to 37.5 kg (55 to 82.5 lb): Initially, 11.25 mg of Depot-Ped I.M. q 4 weeks, increased in increments of 3.75 mg q 4 weeks as needed

Children weighing less than 25 kg (55 lb): Initially, 7.5 mg of Depot-Ped I.M. q 4 weeks, increased in increments of 3.75 mg q 4 weeks as needed

Contraindications

• Hypersensitivity to drug, its components, GnRH, or other GnRH analogs
• Undiagnosed abnormal vaginal bleeding
• Pregnancy or breastfeeding

Precautions

Use cautiously in:
• renal, hepatic, or cardiac impairment.

Administration

• Give Eligard within 30 minutes of mixing. After this time, discard.
• Administer Lupron injection immediately after mixing. Otherwise, discard.
• Administer Lupron Depot-Ped only under prescriber's supervision.

Adverse reactions

CNS: anxiety, depression, dizziness, drowsiness, asthenia, fatigue, headache, vertigo, syncope, mood changes

CV: palpitations, angina, arrhythmias, myocardial infarction

EENT: blurred vision

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, anorexia

GU: urinary frequency, hematuria, decreased testes size, erectile dysfunction, decreased libido, gynecomastia

Hematologic: anemia, thrombocytopenia

Respiratory: dyspnea, pleural rub, worsening of pulmonary fibrosis, pulmonary embolism

Skin: alopecia, pruritus, rash, diaphoresis

Other: sour taste, edema, hot flashes, anaphylaxis

Interactions

Drug-diagnostic tests.Blood urea nitrogen, creatinine: increased levels

Pituitary-gonadal system tests: misleading results during and for up to 3 months after therapy

Patient monitoring

• Observe injection site for local reactions.

Monitor cardiovascular and respiratory status carefully to detect serious adverse reactions.
• Evaluate neurologic status. Institute safety measures as needed to prevent injury.
• Periodically monitor serum testosterone and prostate-specific antigen levels.

Patient teaching

• Inform patient that localized reaction may occur at injection site. Tell him to contact prescriber if symptoms don't resolve.
• Advise patient and family to watch for and report signs or symptoms of depression.
• Tell patient drug may cause libido changes or erectile dysfunction. Encourage him to discuss these problems with prescriber.
• Teach patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.

Instruct female of childbearing age to use reliable contraception during therapy. Tell her to stop drug immediately and contact prescriber if she suspects pregnancy.

Tell female patient not to breastfeed.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

Lupron

(lo͞o′prŏn′)
A trademark for the drug leuprolide acetate.

Lupron

a trademark for a parenteral antineoplastic drug (leuprolide acetate).

Lupron®

Oncology A depot leuprolide, a GnRH–gonadotropin releasing hormone, for palliating advanced prostate CA. See Prostate CA.
References in periodicals archive ?
Abbott's and Takeda's Lupron Depot is a subcutaneously- or intramuscularly-delivered GnRH analogue used to treat advanced androgen-dependent prostate cancers.
The company said the percentage of treatment-compliant subjects receiving 1,500 mg of GTx-758 who achieved target testosterone was comparable to rates seen with treatments like Lupron.
My own story is that after taking Lupron [for endometriosis] I now have bone loss, severe bone and joint pain requiring heavy painkillers to get out of bed, chest pain, tachycardia, fibromyalgia and horrible memory loss, hair loss, and weight gain.
gonadotropin-releasing hormone agonists, such as Lupron.
All women with basal FSH levels < 10 mIU/mL (measured on day 3 of the menstrual cycle) and no previous history of poor gonadotropin stimulation or cycle cancellation, underwent a standard protocol starting with luteal phase Lupron for pituitary suppression.
The subpoena requested information about Lupron, a TAP drug given to treat endometriosis, and Prevacid, used to treat ulcers.
Justice Department began the investigation in December 1997, alleging that TAP provided samples of the cancer drug Lupron Depot to certain physicians with the knowledge that those physicians would claim payment from Medicare and other government programs.
received between $30,000 and $40,000 from billings for free doses of Lupron Depot, which he used to treat cancer patients.
He was also being treated for prostate cancer with a drug called Lupron, which lowers follicle stimulating hormone and leutenizing hormone.
Applicant(s) Bank(s) Bank of Colorado, Burns National Bank of Durango, Fort Lupron, Colorado Durango, Colorado CivicBank of Commerce, East County Bank, Oakland, California Antioch, California Gold Bank, Linn County Bank, Leawood, Kansas La Cygne, Kansas Pinnacle Bank, Pinnacle Bank, Papillion, Nebraska Lincoln, Nebraska Crete State Bank, Crete, Nebraska United States Trust U.
The Lyndhurst Foundation and its chairman Jack Lupron, son of the man who created the Lyndhurst Foundation, donated nearly one-half of the $45 million in private funds that built Chattanooga's most spectacular riverfront attraction, the Tennessee Aquarium.
Then they received both Lupron and one of two consecutively administered hormone replacement therapies.